Summary & Overview
HCPCS Q9973: Injection, Epoetin Beta, 1 mcg (Non-ESRD)
HCPCS Level II code Q9973 denotes a 1 microgram dose of epoetin beta for non–end-stage renal disease (non-ESRD) use. As an HCPCS Level II drug code, it identifies a specific unit of a biologic erythropoiesis-stimulating agent typically administered by injection in outpatient settings such as physician offices, infusion centers, or clinics. This code matters nationally because drug-specific HCPCS billing drives claims processing, unit-based reimbursement, and inventory tracking for injectable biologics used outside dialysis care.
Key payers addressed in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical and billing context for Q9973, including typical sites of service and the service type. The publication outlines what readers can expect: national benchmarks and utilization perspectives where available, relevant policy and coding updates affecting HCPCS drug reporting, and clinical context for epoetin beta use in non-ESRD indications. The summary will also identify gaps where input data is not available and direct readers to sections containing payer coverage notes, coding relationships, and procedural considerations for accurate billing and claims documentation.
Billing Code Overview
HCPCS Level II code Q9973 describes an injection of epoetin beta, 1 microgram, intended for non-ESRD (non–end-stage renal disease) indications. This code denotes the pharmaceutical administration of a synthetic erythropoiesis-stimulating agent in a microdose unit of 1 microgram.
Service Type: Drug administration / Injectable biologic
Typical Site of Service: Outpatient clinic, physician office, or infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with anemia of chronic disease (for example, chemotherapy-induced anemia or anemia associated with chronic inflammatory conditions) who requires outpatient subcutaneous or intramuscular erythropoiesis-stimulating agent therapy. The clinician documents baseline hemoglobin, recent iron studies, and the indication for treatment. A certified medical assistant or nurse prepares and administers a measured dose of epoetin beta drawn from a vial or prefilled syringe in microgram units, monitors the patient for immediate adverse reactions for 15–30 minutes, and documents lot number, dose in micrograms, site of injection, and patient tolerance in the medical record. Billing uses HCPCS Level II code Q9973 to report the quantity of epoetin beta administered (per 1 microgram unit) for non–end-stage renal disease indications. Typical sites of service include oncology or hematology clinics, infusion centers, and ambulatory care clinics. Prior authorization, dosage limits, and documentation of hemoglobin and iron status are commonly required by payors before continued therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | When a separate E/M visit is performed and documented in addition to administration of the medication |